Professor, Pathology, University of Pittsburgh School of Medicine
Pathology
Dr. David J. Dabbs, MD
|
|
Give Review
David Dabbs works in the field of Pathology. He attended University of Toledo College of Medicine. David Dabbs is a published doctor. He has 70 papers published. The most current publication "Dual HER2 Gene Protein Assay: Focused Study of Breast Cancers With 2+ Immunohistochemical Expression." He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Dual HER2 Gene Protein Assay: Focused Study of Breast Cancers With 2+ Immunohistochemical Expression.
- Low ER+ Breast Cancer: Is This a Distinct Group?
- Bright-Field HER2 Dual In Situ Hybridization (DISH) Assay vs Fluorescence In Situ Hybridization (FISH): Focused Study of Immunohistochemical 2+ Cases.
- Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases.
- Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.
- Cancer of unknown primary origin: using ancillary techniques with caution.
- Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
- A validation study of quantum dot multispectral imaging to evaluate hormone receptor status in ductal carcinoma in situ of the breast.
- Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma.
- Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification.
- Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma.
- Oncotype DX Test on Unequivocally HER2-Positive Cases: Potential for Harm.
- High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study.
- NY-BR-1 and PAX8 Immunoreactivity in Breast, Gynecologic Tract, and Other CK7+ Carcinomas: Potential Use for Determining Site of Origin.
- An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature.
- Classical-Type Invasive Lobular Carcinoma With HER2 Overexpression: Clinical, Histologic, and Hormone Receptor Characteristics.
- Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.
- Intracystic papillary carcinomas of the breast are more similar to in situ carcinomas than to invasive carcinoma.
- Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.
- Fixation time does not affect the expression of estrogen receptor.
- Erratum: Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy.
- Immunohistochemical profile of steroid cell tumor of the ovary: a study of 14 cases and a review of the literature.
- Permanently blocked stem cells derived from breast cancer cell lines.
- Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
- Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
- Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
- Basal-like subtype breast cancers in women older than 40 years of age.
- Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
- Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications.
- PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma.
- Clinicopathologic implications of "flat epithelial atypia" in core needle biopsy specimens of the breast.
- Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases.
- Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers.
- Columnar cell lesions and pseudoangiomatous hyperplasia like stroma: is there an epithelial-stromal interaction?
- Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test...
- Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
- CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma.
- Histopathologic variables predict Oncotype DX recurrence score.
- Evaluation of morphologic features to identify "basal-like phenotype" on core needle biopsies of breast.
- Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring sys...
- Pleomorphic lobular carcinoma in pleural fluid: diagnostic pitfall for atypical mesothelial cells.
- Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
- Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases.
- Dissemination of Lean methods to improve Pap testing quality and patient safety.
- Immunohistochemical protocols: back to the future.
- The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.
- The spectrum of morphomolecular abnormalities of the E-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast.
- Asymptomatic giant-cell (temporal) arteritis involving the bilateral adnexa: case report and literature review.
- The clinical significance of lobular neoplasia on breast core biopsy.
- Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin.
- Use of immunohistochemistry in diagnosis of breast epithelial lesions.
- A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ ...
- Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
- Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
- Clinical implications of the diagnosis "atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion" in pregnant women.
- Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
- Clinical significance of cytologic diagnosis of atypical squamous cells, cannot exclude high grade, in perimenopausal and postmenopausal women.
- Molecular alterations in columnar cell lesions of the breast.
- Improving Papanicolaou test quality and reducing medical errors by using Toyota production system methods.
- Selective intraoperative consultation for the evaluation of sentinel lymph nodes in breast cancer.
- Epidermoid metaplasia of the cervix.
- The optimal number of sentinel lymph nodes for focused pathologic examination.
- Intraoperative cytologic examination of breast sentinel lymph nodes: test utility and patient impact.
- Synchronous sentinel lymph node metastasis of lobular and ductal carcinoma.
- Sentinel lymph node micrometastasis as a predictor of axillary tumor burden.
- Utility of intraoperative consultation touch preparations.
- Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma.
- Diagnostic Value of Calretinin in Mast Cell Lesions of the Skin.
Schools
University Of Toledo
Doctors Specialties
- Cytopathology
- Pathology
Accepted Insurances
Education
-
University of Washington -
University of Toledo College of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1770556052 |
| Last Name Of The Provider | DABBS |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Howard N. Douds, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen E. Schoedel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nalini N. Doshi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sydney D. Finkelstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Volker Breitfeld, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martha R. Clarke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susanna B. Levitt, MD |
|
|
Dr. Julia K. Kofler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sara E. Monaco, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alyssa M. Krasinskas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yuri E. Nikiforov, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Gregory J. Naus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Reda S. Saad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cunfeng Pu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Telma C. Pereira, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Peel Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arlette H. Uihlein, MD |
|
|
Dr. Pradeep K. Sethi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Miroslav Djokic, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Debra L. Zynger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Jianwu Xie
This Doctor is OpenDoctor Recommended.
|